Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Duloxetine Hydrochloride; Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Patient has a documented clinical diagnosis of Major Depressive Disorder.

• Be able to understand and comply with the requirements of the study.

• Able to understand and provide written informed consent

Exclusion Criteria:

• Patients (female) must not be pregnant or lactating

• Current or past diagnosis of stroke or transient ischemic attack (TIA).